LONDON (AFX) - Provexis PLC said it has entered into a long-term collaboration agreement with Unilever PLC to jointly develop a new concentrated format of its patented Fruitflow heart-health technology for application in Unilever's food product portfolio.
Financial details of the deal were not disclosed.
The partners plan to enter into a global licence arrangement for the technology.
Fruitflow is a patented natural extract from tomato which Provexis said has been shown in human trials to reduce the propensity for aberrant blood clotting that is typically associated with cardiovascular disease and which can lead to heart attack or stroke.
In 2005 the market for heart benefit foods was worth 4 bln usd globally, Provexis added.
Considering the growth potential this share has a target of about 8-10p in the medium tern and is a good buy at current levels
Worth hanging on to I would say Cynic, unless you need the cash. I know that potential is worth diddly-squat but in this case there does seem to be quite a bit of it!
only ever bought a very modest amount - about 1/4 of my norm followed by a further 1/8 - on basis that it was a complete unknown (to me) and to be honest, i still have no idea as to its upside in say the next 4/6 months.
i suspect that following the massive (speculative) rise over the last 7/10 days, that it will come tumbling back after the figures due from memory in a couple of days
do i need the cash?
no
do i like to see profit dribble away
no
have i done so recently?
yes with GKP though still miles ahead there